

Community-Acquired Pneumonia

A Review

Valerie M. Vaughn, MD, MSc; Robert P. Dickson, MD; Jennifer K. Horowitz, MA; Scott A. Flanders, MD

IMPORTANCE Community-acquired pneumonia (CAP) results in approximately 1.4 million emergency department visits, 740 000 hospitalizations, and 41 000 deaths in the US annually.

OBSERVATIONS Community-acquired pneumonia can be diagnosed in a patient with 2 or more signs (eg, temperature >38 °C or ≤ 36 °C; leukocyte count $<4000/\mu\text{L}$ or $>10\,000/\mu\text{L}$) or symptoms (eg, new or increased cough or dyspnea) of pneumonia in conjunction with consistent radiographic findings (eg, air space density) without an alternative explanation. Up to 10% of patients with CAP are hospitalized; of those, up to 1 in 5 require intensive care. Older adults (≥ 65 years) and those with underlying lung disease, smoking, or immune suppression are at highest risk for CAP and complications of CAP, including sepsis, acute respiratory distress syndrome, and death. Only 38% of patients hospitalized with CAP have a pathogen identified. Of those patients, up to 40% have viruses identified as the likely cause of CAP, with *Streptococcus pneumoniae* identified in approximately 15% of patients with an identified etiology of the pneumonia. All patients with CAP should be tested for COVID-19 and influenza when these viruses are common in the community because their diagnosis may affect treatment (eg, antiviral therapy) and infection prevention strategies. If test results for influenza and COVID-19 are negative or when the pathogens are not likely etiologies, patients can be treated empirically to cover the most likely bacterial pathogens. When selecting empirical antibacterial therapy, clinicians should consider disease severity and evaluate the likelihood of a bacterial infection—or resistant infection—and risk of harm from overuse of antibacterial drugs. Hospitalized patients without risk factors for resistant bacteria can be treated with β -lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days. Systemic corticosteroid administration within 24 hours of development of severe CAP may reduce 28-day mortality.

CONCLUSIONS Community-acquired pneumonia is common and may result in sepsis, acute respiratory distress syndrome, or death. First-line therapy varies by disease severity and etiology. Hospitalized patients with suspected bacterial CAP and without risk factors for resistant bacteria can be treated with β -lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days.

JAMA. 2024;332(15):1282-1295. doi:10.1001/jama.2024.14796
Published online September 16, 2024.

- [+ Multimedia](#)
- [+ Supplemental content](#)
- [+ CME at \[jamacmelookup.com\]\(http://jamacmelookup.com\)](#)

Author Affiliations: Division of General Internal Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City (Vaughn); Division of Health System Innovation & Research, Department of Population Health Science, University of Utah School of Medicine, Salt Lake City (Vaughn); Division of Hospital Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor (Vaughn, Horowitz, Flanders); Division of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor (Dickson); Department of Microbiology & Immunology, University of Michigan, Ann Arbor (Dickson); Weil Institute for Critical Care Research & Innovation, Ann Arbor, Michigan (Dickson).

Corresponding Author: Valerie M. Vaughn, MD, MSc, Division of General Internal Medicine, University of Utah, 30 N 1900 E, Salt Lake City, UT 84132 (valerie.vaughn@hsc.utah.edu).

Section Editor: Kristin Walter, MD, Deputy Editor.

Pneumonia, the most common infectious cause of hospitalization and mortality in adults in the US,¹ occurs when a pathogen infects the lower respiratory tract. The subsequent infection and inflammatory response cause respiratory (eg, cough, dyspnea) and systemic (eg, fever) symptoms, and may lead to sepsis, acute respiratory distress syndrome, and death.² Community-acquired pneumonia (CAP) is defined as pneumonia that is acquired outside the hospital setting or specifically in patients not hospitalized during the 48 hours before diagnosis. As of 2019, CAP includes patients previously classified as having "health care-associated pneumonia" who acquire pneumonia after a recent hospitalization or while in a nursing facility.^{3,4} Community-acquired pneumonia does not include patients with hospital-acquired pneumonia who acquire pneumonia during hospitalization (ie, after more than 48 hours of hospitalization) or those with

ventilator-associated pneumonia who acquire pneumonia while receiving mechanical ventilation.⁴ Although CAP is typically treated in outpatient settings, up to 10% of patients with CAP are hospitalized, resulting in approximately 1.4 million emergency department visits, 740 000 hospitalizations, 41 000 deaths, and \$7.7 billion in inpatient costs each year in the US.^{1,5,6} The US incidence of hospitalization due to CAP is approximately 24.8 per 10 000 person-years for all adults, with a higher incidence (63.0 per 10 000 person-years) in those older than 65 years.⁷ Thirty-day mortality after hospitalization for CAP varies from 2.8% for adults younger than 60 years to 26.8% for those aged 60 years and older and with comorbid conditions.⁸

This Review summarizes current evidence on pathogenesis, epidemiology, diagnosis, and treatment of CAP and focuses on adults without immune-compromising conditions.

Methods

PubMed searches, restricted to English-language articles published within the past 10 years, were performed on December 4, 2023, and updated on March 25, 2024, using title key words “community-acquired pneumonia” and title or abstract key words “epidemiology,” “diagnosis,” or “treatment.” For treatment, the search was limited to randomized clinical trials, systematic reviews, and meta-analyses. For diagnosis and epidemiology, the search was limited to cohort and cross-sectional studies, randomized clinical trials, systematic reviews, and meta-analyses. Additional articles were identified from references of selected articles. Current practice guidelines and societal best practice documents were reviewed for additional references. We prioritized for inclusion meta-analyses, randomized clinical trials, and longitudinal studies along with larger studies and relevance to general medical practice.

Of 549 identified articles, 137 were included, consisting of 57 observational studies, 32 meta-analyses, 27 randomized clinical trials, 10 nonsystematic reviews, 6 systematic reviews without meta-analysis, and 5 practice guidelines (see also eTable 1 in the Supplement).

Discussion

Pathogenesis

The pathogenesis of CAP involves rapid proliferation of bacterial, fungal, or viral pathogens within the alveoli and adjacent small airways, combined with host inflammation, disrupting homeostasis both locally within the lungs (resulting in dyspnea and cough, impaired gas exchange, and radiographic air space consolidation) and systemically (resulting in fever, fatigue, altered mental status, and potentially sepsis) (Figure). Most respiratory viruses, including SARS-CoV-2,⁹ spread via aerosol transmission or airborne particles less than 5 μm that remain suspended in air, bypass surgical masks, and directly access the lower respiratory tract via inhalation, and are typically not spread by short-lived respiratory droplets or by fomites (objects that retain viable pathogens on their surface).^{9,10} This recent discovery has important implications for infection control and public health.^{9,10} Recent advances in understanding of the lung microbiome have challenged long-held assumptions regarding the pathogenesis of bacterial pneumonia. Whereas lungs have traditionally been considered sterile in a healthy individual, recent studies documented that healthy lungs contain diverse communities of bacteria⁹ (mostly of oropharyngeal origin) that are viable,¹¹ are metabolically active,¹² and contribute to the host's dynamic calibration of immune defenses.^{13,14} Thus, rather than representing the invasion of a sterile space by an overwhelming inoculum of a single exogenous pathogen, bacterial pneumonia occurs when an organism emerges as a dominant one from within a changing, complex ecosystem. Factors that result in emergence of a single pathogenic organism within the lung are not fully understood. Potential factors include preceding viral infections, aspiration of large volumes of pharyngeal and gastric contents, or local immune impairment, such as ciliary dysfunction or impaired macrophage function.¹⁴ Furthermore, prior systemic antibacterial use may select for a single organism, or resistant organism, that becomes dominant.

Previously, aspiration pneumonia, defined as pneumonia arising after aspiration of oropharyngeal or gastric contents, was understood to be caused by mixed communities of anaerobic pharyngeal microbiota such as *Bacteroides* species and *Fusobacterium* species. More recent studies of CAP microbiology have identified few anaerobic pathogens^{7,15} and found that bacterial pathogens in patients with CAP with and without clinically suspected aspiration were not meaningfully different.^{15,16}


Epidemiology of CAP

According to a systematic review of 29 observational studies that included hospitalized and ambulatory adult patients with radiologically confirmed pneumonia, older age (≥ 65 years) is the strongest risk factor for CAP.¹⁷ Other risk factors include impaired mucociliary clearance (eg, smoking [adjusted odds ratio {aOR}, 1.57; 95% CI, 1.12-2.77]), underlying lung disease (chronic obstructive pulmonary disease [aOR, 1.99; 95% CI, 0.67-13.53]; asthma [aOR, 1.71; 95% CI, 1.00-4.20]), poor oral health (aOR, 2.78; 95% CI, 1.60-4.40), poor nutritional status (aOR, 6.14; 95% CI, 0.65-11.58) or functional impairment (aOR, 2.13; 95% CI, 0.50-7.94), environmental exposures (eg, metals, dust, fumes), or immunosuppressive therapy (aOR, 3.10; 95% CI, 1.27-15.13).¹⁷ Absolute rates were not provided in this systematic review.

Identification of the microorganism causing CAP is difficult. For example, in the Etiology of Pneumonia in the Community (EPIC) study of 2488 hospitalized patients with CAP,⁷ only 38% of patients who underwent systematic evaluation for organisms (from blood, serum, urine, nasopharyngeal, and oropharyngeal samples, with sputum tested for those with productive coughs; invasive testing [eg, of pleural fluid] was conducted only if indicated as part of clinical care) had a pathogen identified in this study.⁷ Although *Streptococcus pneumoniae* remains the most common bacterial cause of CAP,¹⁸ the EPIC study detected *S pneumoniae* in only 5% of hospitalized patients with CAP,⁷ representing 15% of those with an etiology identified. In contrast, respiratory viruses were identified in 23% of patients (40% with an etiology identified), most commonly human rhinovirus (9%) and influenza A or B (6%).⁷ Because COVID-19 is now a common cause of CAP, EPIC and other epidemiologic studies may not represent current epidemiology of viral CAP (eTable 1 in the Supplement).

Community-acquired pneumonia etiology varies by severity of the pneumonia. Patients with severe illness, such as the 1 in 5 of those hospitalized who require intensive care unit (ICU) stay, are more likely to have a bacterial cause for CAP. For example, in the EPIC study, 19% of patients in the ICU vs 9% of those hospitalized but not in the ICU ($P < .001$) had a bacterial etiology of CAP,⁷ and patients in the ICU had a higher prevalence of *S pneumoniae*, *Staphylococcus aureus*, and Enterobacteriaceae infections.⁷ *Legionella* is a potential etiology for patients with severe CAP or any patient with CAP and exposure to water aerosol (eg, from a hot tub).¹⁹ In contrast, outpatients and younger patients who develop CAP are more likely to have viral infections or atypical pathogens such as *Chlamydia pneumoniae* and *Mycoplasma pneumoniae*.¹⁹ Community-acquired pneumonia epidemiology varies by region, and other pathogens should be considered according to seasonality and geographic region (eg, coccidioidomycosis in the Southwestern US), exposure (eg, to tuberculosis), and immune compromise (eg, *Pneumocystis pneumonia*).

Figure. Ecologic Model of Community-Acquired Pneumonia Pathogenesis



Community-acquired pneumonia occurs when pathogens (bacterial, viral, or fungal) rapidly proliferate within the lower respiratory tract, provoking robust host inflammation, collectively resulting in disruption of local (respiratory) and systemic homeostasis. Like any community, the microbiota of the lower respiratory tract are determined by 3 ecologic factors: migration, elimination, and the relative reproduction rates of microbiota. In health, migration of pharyngeal microbes is common (via subclinical aspiration and inhalation of microbe-laden air) but adequately offset by microbial elimination, and reproduction of viable microbes in the lower respiratory tract is minimal. Community-acquired pneumonia occurs when increased migration, impaired

elimination, and enhanced microbial reproduction together result in the emergence and outgrowth of a dominant pathogen, associated with host inflammation and tissue injury. Local (alveolar) inflammation and tissue injury provoke the respiratory manifestations of community-acquired pneumonia: air space filling, impaired gas exchange, dyspnea, and cough. Dissemination of pathogens and their products, along with host-derived immune mediators (eg, tumor necrosis factor- α), mediates the systemic manifestations and sequelae of community-acquired pneumonia: fever, fatigue, altered mental status, and sepsis.

Diagnosing CAP

Pneumonia is diagnosed by a combination of 2 or more signs (eg, temperature $>38^{\circ}\text{C}$ or $\leq 36^{\circ}\text{C}$; leukocyte count $<4000/\mu\text{L}$ or $>10\,000/\mu\text{L}$) or symptoms (eg, new or increased cough or dyspnea) of pneumonia in conjunction with consistent radiographic findings (eg, air space density) without an alternative explanation for the signs, symptoms, or radiographic findings (Table 1).²² Among 17 290 hospitalized patients with CAP across 48 hospitals, new or worsening cough, sputum production, and dyspnea were the most common symptoms (Table 1).²⁰ Although no individual signs or symptoms have a high sensitivity and specificity for diagnosing CAP when considered alone, a systematic review and meta-analysis of 17 cohort studies found that absence of abnormal vital signs can help rule

out CAP (sensitivity, 93%; negative likelihood ratio, 0.25; 95% CI, 0.11-0.48).²¹ In this study, egophony and dullness to percussion, although uncommon, had a specificity of 0.99% and 0.94%, respectively.²¹ In contrast, other auscultatory findings such as crackles, decreased breath sounds, or rhonchi had mixed sensitivity and specificity.²¹ Altogether, the 48-hospital study found that only 58.6% of 15 211 patients with CAP had any auscultatory findings documented (compared with 42.6% of 2079 patients with an inappropriate diagnosis of CAP); similarly, the meta-analysis found that any abnormality on the lung examination result had a sensitivity of 59% and a specificity of 57% for CAP.²⁰

Because of the poor sensitivity and specificity of clinical signs and symptoms for diagnosing CAP, all patients considered to have

Table 1. Signs, Symptoms, and Radiologic Findings of CAP^a

Sign or symptom of CAP	Prevalence in patients hospitalized with CAP, % ^{20,b}	Sensitivity ^{21,c}	Specificity ^{21,c}
Respiratory symptoms			
New or increased cough	86.5	0.88	0.16
Adverse change or increase in sputum production ^d	51.7	0.52-0.71	0.35-0.52
New or increased dyspnea	79.8	0.63	0.51
Respiratory signs			
Hypoxemia ^d	33.2	0.36	0.83
Auscultatory findings such as egophony or rales	58.6	0.60	0.67
Tachypnea (respiratory rate >20/min)	68.9	0.53	0.84
Infectious signs			
Temperature			
>38 °C or ≤36 °C	60.0	0.63 ^e	0.55 ^a
>38 °C ^d	44.6	0.34	0.87
≤36 °C	41.7	NA	NA
Leukocyte count <4000/μL or >10 000/μL; or >15% bands	68.4	NA	NA

Abbreviations: CAP, community-acquired pneumonia; NA, not available.

^a Pneumonia is diagnosed by a combination of 2 or more of the signs or symptoms of pneumonia in conjunction with consistent radiographic findings without an alternative explanation.

^b Prospective cohort of 17 290 hospitalized, non-intensive care patients with CAP across 48 Michigan hospitals.

^c Systematic review that includes 9 primary care and 7 emergency department-based studies.

^d Definitions between studies varied.

^e Subjective fever was used to assess sensitivity and specificity.

CAP should undergo radiographic evaluation to confirm or exclude the diagnosis.³ Because it is relatively inexpensive and accessible, chest radiography is often the initial diagnostic test, but its sensitivity (median, 70%; range, 16%-95%) and specificity (median, 55%; range, 0%-94%)²³ vary according to image quality and whether there is prior imaging available for comparison. For highest-quality images, a chest radiograph should be obtained with both posterior-anterior and lateral projection while the patient stands upright holding a deep inspiration and without any spinal rotation or obstructing objects, such as cardiac monitors or jewelry. If a chest radiograph does not show evidence of CAP but pneumonia is suspected, chest computed tomography is an appropriate next step; a retrospective study of 3423 patients with cardiorespiratory symptoms who had chest computed tomography and radiography as part of clinical care found that only 43.5% of opacities visible with chest computed tomography were also identified with chest radiography.²³ Chest computed tomography can also better evaluate patients for alternative diagnoses, such as pulmonary embolism, than chest radiograph.²⁴⁻³⁴ Air space opacities or infiltrates are the most common radiographic finding (>95%)²⁰ in CAP; however, they are nonspecific and may be caused by atelectasis, fluid (eg, edema), or aspiration pneumonitis. Less common radiographic findings of pneumonia include pleural effusion (particularly unilateral and with loculations), cavitation, and a masslike appearance.²⁰ Although lung ultrasonography when used by a trained technician has a higher sensitivity (median, 95%; range, 69%-100%) and specificity (median, 75%; range, 0%-100%) than chest radiograph for diagnosing CAP,²⁴⁻³⁴ quality varies among technicians, and the utility of ultrasonography for diagnosing CAP is unclear.³⁵

The lack of highly sensitive and specific clinical findings or diagnostic tests for CAP has led to its substantial overdiagnosis. Approximately 10% to 30% of patients treated for CAP do not meet diagnostic criteria (ie, signs, symptoms, and radiographic findings) for CAP.^{20,22,36,37} Patients without symptoms who have infiltrates on radiographs should not be treated for CAP. Patients with CAP symptoms in combination with radiographic results without physical examination evidence of CAP should undergo

chest computed tomography and be evaluated for alternative causes of their symptoms. The differential diagnosis for pneumonia includes exacerbation of chronic cardiopulmonary diseases (eg, chronic obstructive pulmonary disease), acute upper airway disease (eg, acute bronchitis), aspiration pneumonitis, malignancy, and pulmonary embolus.³ In a study of more than 40 000 inpatient veterans aged 65 years or older and receiving a diagnosis of pneumonia, 9.2% received a diagnosis of pulmonary malignancy after hospital discharge, 27% of which were diagnosed within 90 days of hospitalization.³⁸

Diagnostic Testing for CAP

Not all patients with possible CAP require diagnostic testing to determine the etiology. When diagnostic testing for CAP is considered, the most important question is whether the test result will change management. For example, there are multiple potential benefits of rapid testing for SARS-CoV-2 and influenza, including increased use of and decreased time to administration of antiviral therapy, reduced antibacterial medication use, reduced hospitalization rates, shorter length of hospital stay and lower health care costs, and better infection control practices.³⁹⁻⁴² In contrast, more extensive testing for viruses other than SARS-CoV-2 and influenza has not been shown to affect care.⁴³⁻⁴⁵ Thus, the Infectious Diseases Society of America (IDSA) recommends SARS-CoV-2 and influenza testing for all patients with possible CAP during periods of community transmission or potential exposure to SARS-CoV-2 and influenza (including recent travel to areas with high community transmission); in contrast, IDSA suggests that more extensive testing for viruses other than SARS-CoV-2 and influenza only "be considered in select cases where timely pathogen determination may allow a more directed therapy or discontinuation of unnecessary antibiotics."⁴⁶ Except for viral testing, only patients with severe CAP (ie, meeting IDSA/American Thoracic Society [ATS] severity criteria)³ or risk factors for methicillin-resistant *S aureus* (MRSA) or *Pseudomonas aeruginosa*, or those who do not improve with a course of typical antibacterial medications, should be evaluated for etiology (Table 2).^{47-52,54-56,58-65} Patients with risk factors for

Table 2. Diagnostic Testing in CAP^a

Test	Recommendations	Recommended uses	Test performance and limitations	Diagnostic stewardship considerations ^{47,b}
Recommended in most CAP				
COVID-19 and influenza testing	<p>IDSA recommended if the virus is common in the community (eg, travel to area with community transmission) or if there is potential exposure.⁴⁶</p>	<p>All patients regardless of severity when virus is actively circulating or when the patient has been exposed to these viruses.</p>	<p>When used in ED, influenza testing decreases time to diagnosis, appropriate isolation, time to antiviral initiation, antimicrobial use, chest radiography, admission, and length of stay.^{39,42}</p>	
Recommended in severe CAP and for patients with risk factors for MRSA or Pseudomonas^c				
Blood cultures	<p>Recommended in severe CAP, risk factors for MRSA or Pseudomonas,^{3,46} or empirical treatment of MRSA or Pseudomonas.</p>	<p>Severe CAP; patients at elevated risk of MRSA or Pseudomonas, including those with history of MRSA or Pseudomonas infection or those hospitalized and who received parenteral antibacterial medications in last 90 d. Patients initiating anti-MRSA or anti-Pseudomonas therapy.</p>	<p>For patients with low risk of bacteremia, positive results are more likely false positives. In nonsevere CAP, positive blood culture results rarely change management. Yield reduced by prior antibacterial use.</p>	<p>Two sets of blood cultures should be obtained before initiation of antibacterial treatment. Utility may be improved through rapid diagnostics to quickly identify pathogens and contaminants (eg, coagulase-negative Staphylococci). Optimal collection practices, such as proper disinfection, sample transport, and training of phlebotomists, can reduce contamination rate. Automatic rejection of poor-quality samples. Educate staff on proper collection techniques and need for rapid transport. To improve antibacterial de-escalation, report "no MRSA, no Pseudomonas" when oral flora or negative result.⁵²</p>
Respiratory culture and Gram stain	<p>Recommended in severe CAP, risk factors for MRSA or Pseudomonas,^{3,46} or empirical treatment of MRSA or Pseudomonas.</p>	<p>Severe CAP; patients at higher risk of MRSA or Pseudomonas, including those with history of MRSA or Pseudomonas infection or those hospitalized and who received parenteral antibacterial medications in last 90 d. Patients initiating anti-MRSA or anti-Pseudomonas therapy.</p>	<p>Not all patients can produce high-quality sputum (defined as sample with ≥ 25 leukocytes and < 10 squamous epithelial cells per low-power field), which is associated with diagnostic yield.⁴⁸ Does not detect viruses and some atypical pathogens. Slow (although may improve with rapid diagnostics). Bacteria colonizing the oropharynx can grow; true bacterial infections may not be detected with cultures alone.^{49,50} Gram stains are specific (0.87%-0.99%) but less sensitive (0.59%-0.72%).⁵¹ If negative, then helpful (99% NPV).⁵³ If positive, then unhelpful (35.4% PPV).⁵³</p>	
MRSA nasal swab	<p>Recommended in severe CAP and risk factors for MRSA.^{3,46}</p>	<p>Severe CAP; patients at elevated risk of MRSA, including those with history of MRSA infection or antibacterial medications in last 90 d. Patients initiating anti-MRSA antibacterial medications such as vancomycin or linezolid</p>		<p>Order when anti-MRSA antibacterial medications ordered. Automatic (or facilitated) anti-MRSA cessation if MRSA nares result returns negative.</p>
Pneumococcal urinary antigen	<p>Recommended in severe CAP only.^{3,46}</p>	<p>Patients initiating anti-MRSA/anti-Pseudomonas therapy.</p>	<p>Empirical therapy already covers Streptococcus pneumoniae; thus, pneumococcal urinary antigen testing changes management only if anti-MRSA or anti-Pseudomonas therapy is started.</p>	<p>Consider removing from order sets or other diagnostic stewardship intervention to reduce use (\$100 per test or \$2400 per positive test result).⁵⁴</p>

(continued)

Table 2. Diagnostic Testing in CAP^a (continued)

Test	Recommendations	Recommended uses	Test performance and limitations	Diagnostic stewardship considerations ^{47,b}
Recommended in severe CAP and special uses				
<i>Legionella</i> urine antigen	Recommended in severe CAP or risk factors for <i>Legionella</i> . ^{3,46}	Patients with severe CAP, known exposure, travel, or setting of outbreak. If antibacterial treatment is planned regardless of result, do not order.	Detects only <i>L pneumophila</i> serogroup 1 antigenuria. AUC = 0.77 (95% CI, 0.74-0.81) for identifying CAP, defined in most studies as abnormal chest radiograph result.	Procalcitonin is ineffective when protocols not followed ⁵⁹ ; to improve efficacy, consider implementing with antibiotic stewardship support (eg, discussion during face-to-face stewardship rounds). ⁶⁰
Procalcitonin	IDSA recommends for severe CAP or to guide antibacterial initiation or discontinuation in combination with viral diagnostics. ⁴⁶	Potential uses: When considering starting antibacterial medications for COVID-19 (has high negative predictive value for bacterial infection). As an additional data point when true diagnostic uncertainty exists (eg, alternative diagnosis). In combination with viral testing to withhold or stop antibacterial medications.	AUC = 0.73 (95% CI, 0.69-0.76) for distinguishing viral from bacterial CAP. ^{55,56} May be falsely negative early in infection or with atypical bacteria. May be helpful for its NPV (98.3% for ≤0.1 ng/mL) for bacterial coinfection with SARS-CoV-2. ⁵⁷ One study found it helpful in determining whether to prescribe azithromycin vs levofloxacin in outpatients with CAP. ⁵⁸	
Expanded respiratory viral testing (other than COVID-19 or influenza)	IDSA recommends for severe CAP or in combination with procalcitonin to guide antibacterial initiation or discontinuation. ⁴⁶ ATS recommends for severe CAP. ⁶¹	Severe CAP: in combination with procalcitonin if antibacterial medications would be deferred or stopped.	Expensive; limited data on how results should affect management. No demonstrated effect on antibacterial initiation. ^{62,63} Mixed demonstrated effect on antibacterial duration and discontinuation. ^{40,41,62,63}	Best when combined with recommendations from antibiotic stewardship personnel. For example, 1 study showed that viral panel results combined with a text or phone call explaining results to clinicians resulted in shorter intravenous antibacterial medication regimens, shorter hospital stay, and lower cost of hospitalization. ⁶⁴
Not currently recommended for most CAP				
Invasive lower respiratory tract diagnostic testing	Bronchoscopic sampling, for example. ⁴⁶	More practical and clinically warranted for patients undergoing mechanical ventilation (via bronchoscopic or nonbronchoscopic alveolar lavage or tracheal aspirate).	Achieves high level of pathogen identification ⁶⁵ but no prospective studies demonstrating value.	Rarely indicated in CAP, given need for sedation, procedural risk, and adequacy of empirical regimens.

Abbreviations: ATS, American Thoracic Society; AUC, area under the curve; CAP, community-acquired pneumonia; ED, emergency department; IDSA, Infectious Diseases Society of America; MRSA, methicillin-resistant *Staphylococcus aureus*; NPV, negative predictive value; PPV, positive predictive value.
^a Descriptions of diagnostic tests that may be used in CAP, their indications, and considerations to improve diagnostic use are reported with supporting studies.
^b Diagnostic stewardship involves strategies to modify the process of ordering and performing diagnostic tests and reporting their results to improve the treatment of infections and other conditions.
^c Severe CAP includes patients requiring intensive care or meeting IDSA/ATS severity criteria.

Box. Commonly Asked Questions About Community-Acquired Pneumonia (CAP)

1. What Diagnostic Evaluation Is Recommended for Patients With Possible CAP?

Patients with possible CAP should undergo chest imaging, typically by chest radiography, and be tested for SARS-CoV-2 and influenza if these viruses are prevalent in the patient's community. Further testing for bacterial infection (eg, respiratory or blood cultures) should be performed only if the patient has severe pneumonia (ie, requires vasopressors, requires mechanical ventilation, or has 3 or more minor severity criteria) or risk factors for methicillin-resistant *Staphylococcus aureus* or *Pseudomonas*.

2. What Are the Most Common Causes of CAP?

Only 38% of patients hospitalized with CAP have a pathogen identified. Of those patients, up to 40% have viruses identified as the likely cause of CAP, with *Streptococcus pneumoniae*, the most common bacterial pathogen, identified in approximately 15%.

3. What Antibiotics Should Be Used to Treat CAP?

When a bacterial cause is suspected, patients in the ambulatory setting and without comorbidities may be treated with amoxicillin 1 g 3 times daily or doxycycline 100 mg twice daily. Patients in the ambulatory setting and with comorbidities could be treated with combination therapy (eg, amoxicillin/clavulanate or a cephalosporin such as cefpodoxime or cefuroxime with azithromycin). Hospitalized patients with suspected bacterial CAP and without risk factors for resistant bacteria can be treated with β -lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days. Patients with severe CAP should receive systemic corticosteroids in addition to empirical antibiotic therapy according to whether they have risk factors for resistant bacteria.

MRSA or *Pseudomonas* include those with a history of MRSA or *Pseudomonas* infection and those with a hospitalization in the past 90 days during which parenteral antibacterial medications were administered.

Treatment

The decision to hospitalize a patient with CAP should be made based on clinical judgment and a clinical decision tool.³ The Pneumonia Severity Index, which divides patients into 5 risk categories (I-V, where V is worst), was originally developed to predict 30-day mortality. The index assigns points for patient demographic and clinical variables and was endorsed by the 2019 ATS/IDSA guideline as the preferred tool for site-of-care decisions because of its ability to safely reduce hospital admissions for patients with low risk (ie, Pneumonia Severity Index risk categories I-III, which represent more than two-thirds of patients presenting to the emergency department).³ Because the index can underestimate disease severity, especially for patients aged 50 years or younger, and does not include social determinants of health that may affect the likelihood of successful outpatient treatment (such as homelessness or substance use), clinical judgment should be used when decisions about hospitalization for patients with CAP are made.

Antibacterial Therapy

Empirical antibacterial therapy should be selected according to disease severity and likely pathogen. The 2019 ATS/IDSA guide-

lines categorized hospitalized patients as having severe pneumonia (ie, patient requiring vasopressors or mechanical ventilation, or with 3 or more minor severity criteria)³ or nonsevere pneumonia (all other hospitalized patients). For hospitalized patients with nonsevere bacterial CAP, empirical treatment with a β -lactam, such as ceftriaxone, in combination with a macrolide, such as azithromycin, or fluoroquinolone monotherapy (eg, levofloxacin) was recommended (Box).³ Because of potential harms from fluoroquinolone therapy, such as *Clostridioides difficile* infection, antibacterial resistance, and risk of tendon rupture, fluoroquinolone monotherapy is currently recommended only if a β -lactam/macrolide combination is not tolerated (eg, severe penicillin allergy).⁴⁶ For many patients, this treatment requires determining whether a penicillin allergy exists because, although 10% of the US population reports a penicillin allergy, less than 1% demonstrate a true allergy to penicillin.⁶⁶ Although data are mixed on whether macrolides improve outcomes when added to β -lactam therapy for nonsevere CAP,⁶⁷⁻⁷⁰ the highest-quality observational and clinical trial evidence suggests that macrolides can improve outcomes, potentially including mortality, for severe CAP.^{71,72} The 2024 ACCESS trial reported that compared with placebo, clarithromycin 500 mg twice daily for 7 days reduced a composite end point of respiratory symptom severity and early inflammatory response (68% [91/134] vs 38% [51/133]; $P < .001$).⁷¹ Hospitalized patients with severe CAP should generally receive the same empirical therapy as those with nonsevere CAP (ie, a β -lactam/macrolide combination), with fluoroquinolones such as levofloxacin 750 mg daily or moxifloxacin 400 mg daily replacing macrolides for patients with a contraindication to macrolide therapy.³ Empirical administration of antianaerobic antibacterial medications, such as metronidazole or clindamycin, can disrupt protective gut commensal bacteria, can increase risk of secondary infections (eg, *C difficile* colitis),⁷³ and is associated with an estimated 5% to 6% higher mortality.^{74,75} Thus, the 2019 ATS/IDSA CAP guidelines recommend against prescribing antimicrobial therapy active against anaerobic bacteria, such as metronidazole or clindamycin.³

In an observational study of 88 605 hospitalized patients with pneumonia, anti-MRSA therapy (ie, vancomycin therapy) in addition to standard CAP therapy was associated with higher 30-day mortality (marginal probability, 11.6% vs 8.6%), kidney injury (population-average adjusted risk ratio [aRR], 1.4; 95% CI, 1.3-1.5), *C difficile* infection (aRR, 1.6; 95% CI, 1.3-1.9), vancomycin-resistant *Enterococcus* infection (aRR, 1.6; 95% CI, 1.0-2.3), and secondary gram-negative rod infections (aRR, 1.5; 95% CI, 1.2-1.8).⁷⁶ Absolute rates were not provided in this systematic review. Thus, when deciding whether a patient needs anti-MRSA or antipseudomonal empirical coverage, clinicians should consider potential harm of antibacterial drugs and whether the patient has known risk factors for MRSA or *Pseudomonas*. Multiple studies have attempted to identify risk factors for MRSA or *Pseudomonas*. Although many risk factors have been inconsistent across populations, patients with severe (vs nonsevere) CAP are more likely to have MRSA (5% vs 1%) and *Pseudomonas* (3% vs 1%),⁷ as are those with prior MRSA or *Pseudomonas* infection or recent hospitalization with parenteral antibacterial exposure.^{3,77} Thus, patients with a history of MRSA or *Pseudomonas* infection should be treated empirically for that pathogen while etiologic

testing results (eg, blood and respiratory culture results) are pending. For MRSA, a negative MRSA nasal swab test result has a high negative predictive value (99%), and anti-MRSA therapy can be discontinued for patients who test negative for MRSA via nasal swab.⁵³ Patients hospitalized in the 90 days before a CAP diagnosis, during which they received parenteral antibacterial medications, should be empirically treated for MRSA and *Pseudomonas* only if they have severe CAP; otherwise, they can receive standard CAP therapy while etiologic test results are pending.³

Few data exist to guide empirical treatment for outpatients⁷⁸; the 2019 ATS/IDSA CAP guidelines recommended amoxicillin 1 g 3 times daily or doxycycline 100 mg twice daily for patients without comorbidities and recommended combination therapy (eg, amoxicillin/clavulanate or cephalosporin [such as cefpodoxime or cefuroxime] and azithromycin) for patients with comorbidities such as chronic lung disease or asplenia (Table 3; eTable 2 in the Supplement).^{3,79-124} Fluoroquinolone (eg, levofloxacin) monotherapy is not recommended unless the patient cannot tolerate first-line therapy.⁴⁶

To our knowledge, no randomized clinical trials have examined whether patients with viral CAP should be treated empirically with antibacterial therapy. In retrospective studies, up to 20% of 1488 hospitalized patients who received antibacterial medications experienced an adverse event,¹²⁵ and a single additional day of antibacterial treatment increased the absolute risk of acquiring a resistant organism by 7% (eg, from 10% to 17%).¹²⁶ The long-term effects of antibacterial use on a patient's entire microbiome are not fully understood. However, microbiome changes (from antibacterial use or other causes) have been linked to obesity, chronic inflammation, and cancer.¹²⁷ For COVID-19, the highest-quality retrospective studies suggested that most patients with CAP did not require antibacterial medications. A systematic review of 3338 patients hospitalized with CAP due to COVID-19 reported that 3.5% had a bacterial coinfection on presentation.¹²⁸ If a bacterial coinfection is suspected in a hospitalized patient with COVID-19, procalcitonin testing may be helpful because the negative predictive value of a procalcitonin value less than or equal to 0.1 ng/mL is 98.3%.⁵⁷ In contrast, for patients with COVID-19, the positive predictive value of a procalcitonin level greater than 0.5 ng/mL was approximately 9.3% because coinfection with bacteria is uncommon in patients with CAP due to COVID-19. Therefore, for patients unlikely to have a bacterial coinfection, antibacterial therapy should not be initiated based on a positive procalcitonin value alone.⁵⁷

For non-COVID-19 viruses, the decision to treat should be based on severity of the patient's illness and consideration of host biomarkers such as procalcitonin.⁴⁶ For example, in the EPIC study, 7% of 462 non-ICU inpatients with CAP and a viral pathogen detected had bacterial codetection compared with 15% of 125 ICU patients with viral CAP. Given these findings, IDSA suggests treating viral CAP with antiviral therapy (if indicated), such as oseltamivir for influenza A and B, and considering deferral of antibacterial treatments if there is low suspicion of bacterial coinfection; for example, if serum procalcitonin level is less than or equal to 0.25 ng/mL.⁴⁶ If antibacterial therapy is prescribed, it should supplement disease-specific therapy (eg, steroids, antiviral therapy) and antibacterial medications should be discontinued if a bacterial pathogen is not identified.⁴⁶

De-Escalating Antibacterial Medications

Antibacterial de-escalation includes stopping antibacterial medications, transitioning from empirical to directed therapy, narrowing the spectrum of therapy, or transitioning from intravenous to oral therapy. Clinicians should transition from intravenous to oral antibacterial medications as soon as a patient can ingest oral medications.¹²⁹ One retrospective study of 1021 patients reported that default transition to oral medications (ie, an order set with intravenous antibacterial medications for the first dose followed by oral antibacterial medications on subsequent days) for nonsevere CAP was associated with lower intravenous antibacterial duration, shorter total antibacterial duration, and lower costs.¹⁰³ Most CAP bacterial pathogens do not have antibacterial resistance. For these patients, potential oral antibacterial regimens include amoxicillin/clavulanate or an oral cephalosporin (eg, cefpodoxime) in addition to a total of 1500 mg of azithromycin (ie, 500 mg daily for 3 days or 500 mg on the first day and then 250 mg daily for 4 days), including any doses received intravenously.⁴⁶ A recent study of 7742 patients with sepsis reported that de-escalation from β -lactam therapy to antibiotic treatment with a narrower spectrum (eg, from ceftriaxone to amoxicillin rather than ceftriaxone to amoxicillin/clavulanate) was associated with less development of gram-negative resistance.^{102,105} Given this finding, and that most *S pneumoniae* is sensitive to amoxicillin, amoxicillin 1 g orally 3 times a day may also be an appropriate oral antibiotic to select when transitioning from a more broad-spectrum to a more selective antibiotic.

Although the optimal duration of antibacterial therapy in CAP is unknown, a 2021 clinical trial of 310 hospitalized patients with nonsevere CAP who improved quickly (ie, achieved full vital sign stability by hospital day 3, which requires that patients meet all of the following criteria: afebrile [temperature ≤ 37.8 °C], heart rate < 100 /min, respiratory rate < 24 /per min, no hypoxemia [ie, oxygen saturation as measured by pulse oximetry $\geq 90\%$ or $P_{aO_2} \geq 60$ mm Hg], and systolic blood pressure ≥ 90 mm Hg) reported that 3 days of β -lactam antibacterial therapy was noninferior to 8 days of antibacterial therapy for attaining cure at 15 days (77% vs 68%; between-group difference, 9.42%; 95% CI, -0.38% to 20.04%).^{46,92} Given potential harms of longer antibacterial duration,^{101,126} clinicians should treat patients with the shortest effective duration.⁴⁶ Currently, clinical trial evidence supports 3 days of antibacterial medications for outpatients without severe CAP, including for patients treated and discharged from the emergency department without hospital admission. For inpatients with nonsevere CAP, approximately 50% of patients will stabilize by hospital day 3 and should receive antimicrobials for a total of 3 days.^{92,94-97} Patients who take more than 3 days to clinically stabilize should generally receive a total of 5 days of antimicrobial treatment.⁹³ Data are limited on the optimal duration of treating patients who experience complications from pneumonia (eg, empyema) or MRSA or *Pseudomonas* infections, but longer durations of antimicrobials are typically recommended (eg, ≥ 7 days).³

Steroids

For COVID-19 pneumonia associated with hypoxia, clinical trial data, including the 2020 RECOVERY trial, demonstrated that low-dose corticosteroids (ie, dexamethasone 6 mg daily for 10 days) can reduce mortality (28-day mortality of 25.7% without dexamethasone vs

Table 3. Recommended Treatment for CAP^a

Treatment	Treatment recommendations	Evidence summary ^b	Additional considerations or best practices
Antibacterial therapy			
Empirical therapy	<p>Outpatient: amoxicillin or doxycycline alone. If comorbidities (eg, chronic lung disease or asplenia): amoxicillin/clavulanate or oral cephalosporin (ie, cefpodoxime or cefuroxime) and macrolide or doxycycline (respiratory fluoroquinolone if confirmed allergy).</p> <p>Inpatient, nonsevere: β-lactam (eg, ampicillin + sulbactam or ceftriaxone) + macrolide. Respiratory fluoroquinolone only if confirmed allergy.</p> <p>Inpatient, severe: β-lactam (eg, ampicillin + sulbactam or ceftriaxone) + macrolide. If unable to tolerate macrolide, replace with respiratory fluoroquinolone.</p>	<p>Little evidence supporting superiority of one regimen over another.</p> <p>Outpatient: multiple RCTs have not shown evidence of superiority of one therapy over another.⁷⁹</p> <p>Inpatient CAP: multiple systematic reviews found no difference in clinical outcomes between different regimens.⁸⁰⁻⁸⁸ Mortality may be higher with β-lactam + fluoroquinolone combination (compared with β-lactam ± macrolide).^{81,89}</p> <p>Inpatient, severe: addition of macrolide associated with earlier clinical response and potentially lower mortality.^{71,72}</p>	<p>Given risk of resistance and harm with fluoroquinolone use, recommend against empirical fluoroquinolone use when alternative available.⁴⁶ Penicillin allergy is overreported and wanes. Patients with a low-risk allergy history (eg, family history only, reaction >10 y ago or unknown, nonallergic symptoms) can be listed as having no allergy or can have an amoxicillin challenge.⁹⁰ Best trial evidence supports oral clarithromycin for severe CAP,⁷¹ although it has not been directly compared with azithromycin. Data supporting addition of a macrolide to β-lactam for nonsevere inpatient CAP are mixed.</p>
Anti-MRSA coverage	<p>Outpatient: no anti-MRSA therapy recommended.</p> <p>Inpatient, nonsevere: only if prior respiratory isolation of MRSA or if risk factors and culture results return positive for MRSA.</p> <p>Inpatient, severe: with prior respiratory isolation of MRSA or recent hospitalization with parenteral antibacterial medications.</p> <p>When needed, use vancomycin or linezolid.</p>	<p>In an observational study, higher mortality, kidney injury, <i>Clostridioides difficile</i> infection, vancomycin-resistant <i>Enterococcus</i> infection, and secondary gram-negative rod infections with anti-MRSA therapy, a finding consistent across subgroups (eg, severity).⁷⁶</p>	<p>Avoid anti-MRSA therapy for most patients. If MRSA coverage added, obtain MRSA via nasal swab and stop therapy if result is negative.</p>
Antipseudomonal (and other potentially multidrug-resistant nonfermenting gram-negative bacilli)	<p>Outpatient: no coverage recommended.</p> <p>Inpatient, nonsevere: only if prior respiratory isolation of <i>Pseudomonas aeruginosa</i> or if risk factors and culture result returns positive.</p> <p>Inpatient, severe: with prior respiratory isolation of <i>P aeruginosa</i> or recent hospitalization with parenteral antibacterial medications.</p> <p>When needed, cefepime may be preferable to piperacillin-tazobactam.⁹¹ Alternative agents: ceftazidime, imipenem, or meropenem.</p>	<p>In observational cohort studies, use of piperacillin-tazobactam (and other antianaerobic regimens) was associated with higher mortality and longer duration of organ failure.^{74,75,91}</p>	<p>Avoid antipseudomonal therapy for most patients. If started, obtain blood and respiratory cultures, and discontinue in 48 h unless positive.</p>
Antibacterial duration	<p>Outpatient: 3 d.</p> <p>Inpatient (including non-ICU severe CAP): 3 d if stable by day 3⁹²; 5 d if stable by day 5.⁹³ At least 7 d if MRSA, <i>Pseudomonas</i>. Longer durations for complications (eg, empyema) or unusual pathogens (eg, fungi).</p> <p>ICU CAP: patients admitted to intensive care excluded from duration clinical trials.⁹²</p> <p>Stability criteria: 3-d stability requires patients meet all of the following stability criteria by day 3: afebrile (≤37.8 °C), heart rate <100/min, respiratory rate <24/min, no hypoxemia (ie, Sp_{o2} ≥90% or Pao₂ ≥60 mm Hg), and systolic blood pressure ≥90 mm Hg⁹²; 5-d stability requires patients be afebrile plus ≤1 sign of instability by day 5.⁹²</p>	<p>Outpatient: 1-d azithromycin has clinical cure similar to that of 7- to 10-d duration.^{94,95}</p> <p>Inpatient, nonsevere: 3-5 d (depending on time to stability) noninferior to longer durations.^{92,93,96-98}</p> <p>ICU CAP: no studies found.</p>	<p>Prescribe only minimum necessary therapy; observational studies found excessive duration linked to harm^{97,99} and appropriately short courses safe up to 1 y later.¹⁰⁰ For hospitalized patients, ≈50% will be stable by day 3. Up to 90% will be stable by day 5.¹⁰¹ Patients not stable by days 3-5 should be evaluated for alternative diagnoses or noncovered pathogens.</p>
Transition to oral antibacterial medications	<p>Transition to oral antibacterial medications as soon as the patient is improving and able to tolerate oral therapy.³</p> <p>Recommended options for patients without an identified organism^{46,102}: amoxicillin/clavulanate 500 mg/125 mg orally 3 times a day or 875-2000 mg/125 mg orally twice daily; cefpodoxime 200 mg orally twice daily; cefuroxime 500 mg orally twice daily; amoxicillin 1 g orally 3 times a day; plus total 1500 mg azithromycin (including any parenteral doses).</p>	<p>Automatic transition to oral therapy (in nonsevere CAP) can reduce IV and total antibacterial therapy, cost, and LOS.^{46,103,104} Quicker de-escalation (to narrower antibacterial medications [eg, amoxicillin]) may be associated with less development of antibacterial resistance.¹⁰⁵</p>	<p>IV therapy places patients at risk of IV-related harm while increasing cost of care.</p>

(continued)

Table 3. Recommended Treatment for CAP^a (continued)

Treatment	Treatment recommendations	Evidence summary ^b	Additional considerations or best practices
Other treatment			
Steroids	Outpatient: no steroids. Inpatient, nonsevere: no steroids. Inpatient, severe ^c : steroids (eg, hydrocortisone 200 mg/d) ¹⁰⁶ within 24 h of meeting severity criteria.	Outpatient: no studies found. Inpatient, nonsevere: steroids reduce LOS but increase hyperglycemia. No difference in mortality. ^{107,108} Inpatient, mixed severity: data mixed but benefit driven by more severe subgroups. ¹⁰⁹⁻¹¹³ Inpatient, severe: steroids reduce mortality, need for mechanical ventilation, ^c vasopressor use, and hospital or ICU LOS ^{106,114-120} ; adverse events not increased by steroids. ^{115,121}	Patients may require steroids for other pulmonary (eg, asthma, COPD) or disease indications (eg, COVID-19). Patients with influenza pneumonia were excluded from clinical trials owing to concern steroids could be harmful.
Secondary prevention (no clinical trial data)			
Vaccination ¹²²	For outpatients, plan for all eligible vaccinations. For inpatients, offer all eligible vaccinations before discharge: pneumococcal conjugate vaccine, influenza, SARS-CoV-2, respiratory syncytial virus.	Vaccination may reduce infection incidence and severity.	
Tobacco use ¹²²	Screen for and treat tobacco use, including cessation counseling and medications.	Cigarettes increase risk of pneumonia and recurrent pneumonia. ¹⁷	For patients at higher risk of lung cancer, consider recommending lung cancer screening if chest imaging insufficient.
General aspiration risk (dysphagia, alcohol abuse, oral health) ¹²²	Screen for and treat alcoholism and substance use disorders. Recommend good oral hygiene, including toothbrushing. ¹²³ If dysphagia, consider speech evaluation and therapy.	Patients with alcoholism and other substance use disorders are at higher risk of pneumonia and recurrent pneumonia. Poor oral hygiene is a risk factor for CAP. ¹⁷	
Comorbidity management	Ensure all cardiac (eg, heart failure) and pulmonary (eg, COPD, asthma) comorbidities are treated per guidelines, with goal-directed therapy restarted before discharge.	Patients with COPD treated with inhaled steroids are at higher risk for CAP. ¹²⁴ Readmission with heart failure common after pneumonia admission; restart any diuretics or goal-directed medical therapy before discharge. ¹⁰²	Patients with COPD or asthma who are hospitalized with pneumonia may qualify for controller medication augmentation.

Abbreviations: CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IV, intravenous; LOS, length of stay; MRSA, methicillin-resistant *Staphylococcus aureus*; RCT, randomized clinical trial; SpO₂, oxygen saturation as measured by pulse oximetry.

^a Recommended treatment and considerations for best practice, with supporting evidence, are provided by disease severity. American Thoracic Society/Infectious Diseases Society of America criteria were used to distinguish severe from nonsevere inpatient pneumonia unless otherwise stated.

^b See eTable 2 in the Supplement for a detailed literature review included in the evidence summary.

^c The CAPE COD clinical trial defined severe pneumonia by the presence of at least 1 of the following: (1) mechanical ventilation; (2) high-flow nasal cannula with a ratio of Pao₂ to the fraction of inspired oxygen (FIO₂) of less than 300, with FIO₂ greater than or equal to 50%; (3) Pao₂:FIO₂ ratio less than 300 for patients wearing a nonbreathing mask; or (4) Pulmonary Severity Index score greater than 130 (ie, group V severity).¹⁰⁶

22.9% with it), particularly among patients undergoing invasive mechanical ventilation (28-day mortality of 41.4% without dexamethasone vs 29.3% with it).^{130,131}

For non-COVID-19 severe CAP,¹³² clinical trial evidence, including the 2023 CAPE COD trial, suggested that early (ie, within 24 hours of meeting severity criteria) administration of steroids (defined as ≤400 mg hydrocortisone equivalent daily) can reduce 28-day mortality by up to 5.6% (absolute difference, from 11.9% to 6.2%), need for mechanical ventilation, vasopressor use, and length of stay.^{106,109,114,115}

Nonsevere CAP (without alternative indications) appears not to benefit from corticosteroids, largely because outcomes are better in this group, and the risks of adverse effects from steroids outweigh potential benefits.^{107,133,134}

Secondary Prevention

Patients with a history of CAP have higher rates of subsequent CAP (aOR, 1.86; 95% CI, 1.53-3.81)¹⁷ and should be counseled about

smoking and alcohol cessation and relevant vaccination. Relevant vaccines include pneumococcal conjugate vaccine and those for influenza, SARS-CoV-2, and respiratory syncytial virus. Patients should also be counseled about good oral hygiene (ie, daily toothbrushing and dental care to reduce microbial burden)¹²³ and should be treated according to guidelines for underlying cardiac and pulmonary conditions (Table 3).^{122,135} Patients with history of aspiration should be referred for speech or swallow therapy and counseled on behavioral strategies to reduce aspiration. For example, eating with small bites, fully chewing each bite, consuming small frequent meals, and sitting upright during and for 30 minutes after meals can reduce aspiration rates.

Limitations

This review has several limitations. First, not all aspects of CAP were discussed. Second, the literature search may have missed relevant articles. Third, a formal quality assessment of published literature was not performed.

Conclusions

Community-acquired pneumonia is the most common infectious cause of morbidity and mortality in the US. Viruses are the most common pathogens detected in CAP, whereas *S pneumoniae* remains the most common bacterial pathogen. First-line therapy varies by disease severity and by the most likely etiology. Patients with CAP with suspected bacterial cause who do not have comor-

bidiities and are not hospitalized may be treated with amoxicillin 1 g 3 times daily or doxycycline 100 mg twice daily. Patients with CAP with suspected bacterial cause and comorbidities who are not hospitalized should receive combination therapy (eg, amoxicillin/clavulanate, cephalosporin and azithromycin). Hospitalized patients with suspected bacterial CAP and without risk factors for resistant bacteria can be treated with β -lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days.

ARTICLE INFORMATION

Accepted for Publication: July 8, 2024.

Published Online: September 16, 2024.
doi:10.1001/jama.2024.14796

Author Contributions: Drs Vaughn and Flanders had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interest Disclosures: Dr Vaughn reported receiving grants from the Agency for Healthcare Research and Quality (K08HS026530) during the conduct of the study. Dr Dickson reported grants from the National Heart, Lung, and Blood Institute (R01HL144599, K24HL159247, and U01HL168308). Dr Flanders reported being the Michigan Hospital Medicine Safety Consortium (HMS) program director; HMS is funded by Blue Cross Blue Shield of Michigan. No other disclosures were reported.

Additional Contributions: We thank Emily Spivak, MD, MHS (Division of Infectious Diseases, Department of Internal Medicine, University of Utah School of Medicine), for her assistance and expertise during manuscript conceptualization. She received no compensation for her contributions.

Submissions: We encourage authors to submit papers for consideration as a Review. Please contact Kristin Walter, MD, at kristin.walter@jamanetwork.org.

REFERENCES

- McDermott KW, Roemer M. Most frequent principal diagnoses for inpatient stays in US hospitals, 2018. Published July 2021. Accessed December 14, 2023. <https://hcup-us.ahrq.gov/reports/statbriefs/sb277-Top-Reasons-Hospital-Stays-2018.pdf#:~:text=The%20most%20of%20principal%20diagnoses%20for%20hospitalizations%20in,caused%20by%20tuberculosis%29%2C%20and%20diabetes%20mellitus%20with%20complication>
- Rhee C, Jones TM, Hamad Y, et al; Centers for Disease Control and Prevention (CDC) Prevention Epicenters Program. Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals. *JAMA Netw Open*. 2019;2(2):e187571. doi:10.1001/jamanetworkopen.2018.7571
- Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med*. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST
- American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-

associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med*. 2005;171(4):388-416. doi:10.1164/rccm.200405-6445T

5. Sterrantino C, Trifirò G, Lapi F, et al. Burden of community-acquired pneumonia in Italian general practice. *Eur Respir J*. 2013;42(6):1739-1742. doi:10.1183/09031936.00128713

6. Partouche H, Lepoutre A, Vaure CBD, Poisson T, Toubiana L, Gilberg S. Incidence of all-cause adult community-acquired pneumonia in primary care settings in France. *Med Mal Infect*. 2018;48(6):389-395. doi:10.1016/j.medmal.2018.02.012

7. Jain S, Self WH, Wunderink RG, et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among US adults. *N Engl J Med*. 2015;373(5):415-427. doi:10.1056/NEJMoa1500245

8. Theilacker C, Sprenger R, Leverkus F, et al. Population-based incidence and mortality of community-acquired pneumonia in Germany. *PLoS One*. 2021;16(6):e0253118. doi:10.1371/journal.pone.0253118

9. Klompas M, Baker MA, Rhee C. Coronavirus disease 2019's challenges to infection control dogma regarding respiratory virus transmission. *Clin Infect Dis*. 2022;75(1):e102-e104. doi:10.1093/cid/ciac204

10. Wang CC, Prather KA, Sznitman J, et al. Airborne transmission of respiratory viruses. *Science*. 2021;373(6558):eabd9149. doi:10.1126/science.abd9149

11. Venkataraman A, Bassis CM, Beck JM, et al. Application of a neutral community model to assess structuring of the human lung microbiome. *mBio*. 2015;6(1):e02284-14. doi:10.1128/mBio.02284-14

12. Sulaiman I, Wu BG, Li Y, et al. Functional lower airways genomic profiling of the microbiome to capture active microbial metabolism. *Eur Respir J*. 2021;58(1):2003434. doi:10.1183/13993003.03434-2020

13. Segal LN, Clemente JC, Tsay JC, et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. *Nat Microbiol*. 2016;1:16031. doi:10.1038/nmicrobiol.2016.31

14. Dickson RP, Erb-Downward JR, Falkowski NR, Hunter EM, Ashley SL, Huffnagle GB. The lung microbiota of healthy mice are highly variable, cluster by environment, and reflect variation in baseline lung innate immunity. *Am J Respir Crit Care Med*. 2018;198(4):497-508. doi:10.1164/rccm.201711-2180OC

15. Marin-Corral J, Pascual-Guardia S, Amati F, et al; GLIMP Investigators. Aspiration risk factors, microbiology, and empiric antibiotics for patients hospitalized with community-acquired pneumonia.

Chest. 2021;159(1):58-72. doi:10.1016/j.chest.2020.06.079

16. Kitsios GD, Nguyen VD, Sayed K, et al. The upper and lower respiratory tract microbiome in severe aspiration pneumonia. *iScience*. 2023;26(6):106832. doi:10.1016/j.isci.2023.106832

17. Almirall J, Serra-Prat M, Bolibar I, Balaso V. Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies. *Respiration*. 2017;94(3):299-311. doi:10.1159/000479089

18. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. *Pneumonia (Nathan)*. 2020;12:11. doi:10.1186/s41479-020-00074-3

19. Arnold FW, Summersgill JT, Ramirez JA. Role of atypical pathogens in the etiology of community-acquired pneumonia. *Semin Respir Crit Care Med*. 2016;37(6):819-828. doi:10.1055/s-0036-1592121

20. Gupta AB, Flanders SA, Petty LA, et al. Inappropriate diagnosis of pneumonia among hospitalized adults. *JAMA Intern Med*. 2024;184(5):548-556. doi:10.1001/jamainternmed.2024.0077

21. Ebell MH, Chupp H, Cai X, Bentivegna M, Kearney M. Accuracy of signs and symptoms for the diagnosis of community-acquired pneumonia: a meta-analysis. *Acad Emerg Med*. 2020;27(7):541-553. doi:10.1111/acem.13965

22. White AT, Vaughn VM, Petty LA, et al. Development of patient safety measures to identify inappropriate diagnosis of common infections. *Clin Infect Dis*. 2024;78(6):1403-1411. doi:10.1093/cid/ciae044

23. Self WH, Courtney DM, McNaughton CD, Wunderink RG, Kline JA. High discordance of chest x-ray and computed tomography for detection of pulmonary opacities in ED patients: implications for diagnosing pneumonia. *Am J Emerg Med*. 2013;31(2):401-405. doi:10.1016/j.ajem.2012.08.041

24. Amatya Y, Rupp J, Russell FM, Saunders J, Bales B, House DR. Diagnostic use of lung ultrasound compared to chest radiograph for suspected pneumonia in a resource-limited setting. *Int J Emerg Med*. 2018;11(1):8. doi:10.1186/s12245-018-0170-2

25. Bitar ZI, Maadarani OS, El-Shably AM, Al-Ajmi MJ. Diagnostic accuracy of chest ultrasound in patients with pneumonia in the intensive care unit: a single-hospital study. *Health Sci Rep*. 2018;2(1):e102. doi:10.1002/hsr2.102

26. Bourcier JE, Paquet J, Seinger M, et al. Performance comparison of lung ultrasound and chest x-ray for the diagnosis of pneumonia in the ED. *Am J Emerg Med*. 2014;32(2):115-118. doi:10.1016/j.ajem.2013.10.003

27. Corradi F, Brusasco C, Garlaschi A, et al. Quantitative analysis of lung ultrasonography for the detection of community-acquired pneumonia: a pilot study. *Biomed Res Int*. 2015;2015:868707. doi:10.1155/2015/868707
28. Cortellaro F, Colombo S, Coen D, Duca PG. Lung ultrasound is an accurate diagnostic tool for the diagnosis of pneumonia in the emergency department. *Emerg Med J*. 2012;29(1):19-23. doi:10.1136/emj.2010.101584
29. Dhawan J, Singh G. Bedside lung ultrasound as an independent tool to diagnose pneumonia in comparison to chest X-ray: an observational prospective study from intensive care units. *Indian J Crit Care Med*. 2022;26(8):920-929. doi:10.5005/jp-journals-10071-24283
30. Gibbons RC, Magee M, Goett H, et al. Lung ultrasound vs chest X-ray study for the radiographic diagnosis of COVID-19 pneumonia in a high-prevalence population. *J Emerg Med*. 2021;60(5):615-625. doi:10.1016/j.jemermed.2021.01.041
31. Karimi E. Comparing sensitivity of ultrasonography and plain chest radiography in detection of pneumonia: a diagnostic value study. *Arch Acad Emerg Med*. 2019;7(1):e8.
32. Liu XL, Lian R, Tao YK, Gu CD, Zhang GQ. Lung ultrasonography: an effective way to diagnose community-acquired pneumonia. *Emerg Med J*. 2015;32(6):433-438. doi:10.1136/emj-2013-203039
33. Taghizadieh A, Ala A, Rahmani F, Nadi A. Diagnostic accuracy of chest x-ray and ultrasonography in detection of community acquired pneumonia: a brief report. *Emerg (Tehran)*. 2015;3(3):114-116.
34. Auf F, Abo-Naghl A, Zeden M, Al-Sokromi M. Role of transthoracic ultrasound in detection of pneumonia in ICU patients. Accessed March 21, 2024. <https://www.medicaljournalofcairouniversity.net/images/pdf/2015/June/38.pdf>
35. Strøm JJ, Haugen PS, Hansen MP, Graumann O, Jensen MBB, Aakjær Andersen C. Accuracy of lung ultrasonography in the hands of non-imaging specialists to diagnose and assess the severity of community-acquired pneumonia in adults: a systematic review. *BMJ Open*. 2020;10(6):e036067. doi:10.1136/bmjopen-2019-036067
36. Atamna A, Shiber S, Yassin M, Drescher MJ, Bishara J. The accuracy of a diagnosis of pneumonia in the emergency department. *Int J Infect Dis*. 2019;89:62-65. doi:10.1016/j.ijid.2019.08.027
37. Gupta A, Petty L, Gandhi T, et al. Overdiagnosis of urinary tract infection linked to overdiagnosis of pneumonia: a multihospital cohort study. *BMJ Qual Saf*. 2022;31(5):383-386. doi:10.1136/bmjqs-2021-013565
38. Mortensen EM, Copeland LA, Pugh MJ, et al. Diagnosis of pulmonary malignancy after hospitalization for pneumonia. *Am J Med*. 2010;123(1):66-71. doi:10.1016/j.amjmed.2009.08.009
39. Clark TW, Beard KR, Brendish NJ, et al. Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial. *Lancet Respir Med*. 2021;9(4):419-429. doi:10.1016/S2213-2600(20)30469-0
40. Brendish NJ, Malachira AK, Armstrong L, et al. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. *Lancet Respir Med*. 2017;5(5):401-411. doi:10.1016/S2213-2600(17)30120-0
41. Keske Ş, Ergönül Ö, Tutucu F, Karaaslan D, Palaoglu E, Can F. The rapid diagnosis of viral respiratory tract infections and its impact on antimicrobial stewardship programs. *Eur J Clin Microbiol Infect Dis*. 2018;37(4):779-783. doi:10.1007/s10096-017-3174-6
42. Rappo U, Schuetz AN, Jenkins SG, et al. Impact of early detection of respiratory viruses by multiplex PCR assay on clinical outcomes in adult patients. *J Clin Microbiol*. 2016;54(8):2096-2103. doi:10.1128/JCM.00549-16
43. Afzal Z, Minard CG, Stager CE, Yu VL, Musher DM. Clinical diagnosis, viral PCR, and antibiotic utilization in community-acquired pneumonia. *Am J Ther*. 2016;23(3):e766-e772. doi:10.1097/MJT.000000000000018
44. Gilbert D, Gelfer G, Wang L, et al. The potential of molecular diagnostics and serum procalcitonin levels to change the antibiotic management of community-acquired pneumonia. *Diagn Microbiol Infect Dis*. 2016;86(1):102-107. doi:10.1016/j.diagmicrobio.2016.06.008
45. Rezkalla J, Hoover SE, Hsu J, Lamfers R. The impact of molecular testing for pathogens of community-acquired pneumonia on antibiotic utilization. *S D Med*. 2019;72(2):63-66.
46. Infectious Diseases Society of America. CAP clinical pathway. Accessed February 2, 2024. <https://www.idsociety.org/globalassets/idsa/practice-guidelines/community-acquired-pneumonia-in-adults/cap-clinical-pathway-final-online.pdf>
47. Morgan DJ, Malani P, Diekema DJ. Diagnostic stewardship—leveraging the laboratory to improve antimicrobial use. *JAMA*. 2017;318(7):607-608. doi:10.1001/jama.2017.8531
48. Ogawa H, Kitsios GD, Iwata M, Terasawa T. Sputum gram stain for bacterial pathogen diagnosis in community-acquired pneumonia: a systematic review and bayesian meta-analysis of diagnostic accuracy and yield. *Clin Infect Dis*. 2020;71(3):499-513. doi:10.1093/cid/ciz876
49. Haessler S, Lindenauer PK, Zilberberg MD, et al. Blood cultures versus respiratory cultures: 2 different views of pneumonia. *Clin Infect Dis*. 2020;71(7):1604-1612. doi:10.1093/cid/ciz1049
50. Albin OR, Pogue JM, Petty LA, Kaye KS. Asymptomatic bacterisputa: rethinking diagnostic stewardship in pneumonia. *Infect Control Hosp Epidemiol*. 2021;42(6):737-739. doi:10.1017/ice.2021.109
51. Del Rio-Pertuz G, Gutiérrez JF, Triana AJ, et al. Usefulness of sputum gram stain for etiologic diagnosis in community-acquired pneumonia: a systematic review and meta-analysis. *BMC Infect Dis*. 2019;19(1):403. doi:10.1186/s12879-019-4048-6
52. Musgrove MA, Kenney RM, Kendall RE, et al. Microbiology comment nudge improves pneumonia prescribing. *Open Forum Infect Dis*. 2018;5(7):ofy162. doi:10.1093/ofid/ofy162
53. Dangerfield B, Chung A, Webb B, Seville MT. Predictive value of methicillin-resistant *Staphylococcus aureus* (MRSA) nasal swab PCR assay for MRSA pneumonia. *Antimicrob Agents Chemother*. 2014;58(2):859-864. doi:10.1128/AAC.01805-13
54. Bathina P, Lewis HM, Ordaz V. Trends, outcomes and cost analysis of *Streptococcus* urinary antigen testing. *Open Forum Infect Dis*. 2020;7(suppl 1):S381. doi:10.1093/ofid/ofaa439.837
55. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. *Clin Infect Dis*. 2020;70(3):538-542. doi:10.1093/cid/ciz545
56. Ebell MH, Bentivegna M, Cai X, Hulme C, Kearney M. Accuracy of biomarkers for the diagnosis of adult community-acquired pneumonia: a meta-analysis. *Acad Emerg Med*. 2020;27(3):195-206. doi:10.1111/acem.13889
57. Vaughn VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. *Clin Infect Dis*. 2021;72(10):e533-e541. doi:10.1093/cid/ciaa1239
58. Masiá M, Padilla S, Ortiz de la Tabla V, González M, Bas C, Gutiérrez F. Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: a single-arm clinical trial. *PLoS One*. 2017;12(4):e0175634. doi:10.1371/journal.pone.0175634
59. Huang DT, Yealy DM, Filbin MR, et al; ProACT Investigators. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. *N Engl J Med*. 2018;379(3):236-249. doi:10.1056/NEJMoa1802670
60. Langford BJ, Beriault D, Schwartz KL, et al. A real-world assessment of procalcitonin combined with antimicrobial stewardship in a community ICU. *J Crit Care*. 2020;57:130-133. doi:10.1016/j.jcrc.2020.02.009
61. Evans SE, Jennerich AL, Azar MM, et al. Nucleic acid-based testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia: an official American Thoracic Society clinical practice guideline. *Am J Respir Crit Care Med*. 2021;203(9):1070-1087. doi:10.1164/rccm.202102-0498ST
62. Andrews D, Chetty Y, Cooper BS, et al. Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use. *BMC Infect Dis*. 2017;17(1):671. doi:10.1186/s12879-017-2784-z
63. Cartuliales MB, Rosenvinge FS, Mogensen CB, et al. Evaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark: a multicentre randomised controlled trial. *PLoS Med*. 2023;20(11):e1004314. doi:10.1371/journal.pmed.1004314
64. Shengchen D, Gu X, Fan G, et al. Evaluation of a molecular point-of-care testing for viral and atypical pathogens on intravenous antibiotic duration in hospitalized adults with lower respiratory tract infection: a randomized clinical trial. *Clin Microbiol Infect*. 2019;25(11):1415-1421. doi:10.1016/j.cmi.2019.06.012

65. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. *Clin Infect Dis*. 2016;62(7):817-823. doi:10.1093/cid/civ1214
66. Centers for Disease Control and Prevention. Is it really a penicillin allergy? evaluation and diagnosis of penicillin allergy for healthcare professionals. Accessed January 22, 2024. <https://www.cdc.gov/antibiotic-use/media/pdfs/penicillin-factsheet-508.pdf>
67. Postma DF, van Werkhoven CH, van Elden LJ, et al; CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. *N Engl J Med*. 2015;372(14):1312-1323. doi:10.1056/NEJMoa1406330
68. Nie W, Li B, Xiu Q. β -Lactam/macrolide dual therapy versus β -lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. *J Antimicrob Chemother*. 2014;69(6):1441-1446. doi:10.1093/jac/dku033
69. Horita N, Otsuka T, Haranaga S, et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis. *Respirology*. 2016;21(7):1193-1200. doi:10.1111/resp.12835
70. Garin N, Genné D, Carballo S, et al. β -Lactam monotherapy vs β -lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. *JAMA Intern Med*. 2014;174(12):1894-1901. doi:10.1001/jamainternmed.2014.4887
71. Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. *Lancet Respir Med*. 2024;12(4):294-304. doi:10.1016/S2213-2600(23)00412-5
72. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. *Crit Care Med*. 2014;42(2):420-432. doi:10.1097/CCM.0b013e3182a66b9b
73. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated *Clostridium difficile* infection and antibiotics: a meta-analysis. *J Antimicrob Chemother*. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129
74. Chanderraj R, Baker JM, Kay SG, et al. In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomes. *Eur Respir J*. 2023;61(2):2200910. doi:10.1183/13993003.00910-2022
75. Kullberg RFJ, Schinkel M, Wiersinga WJ. Empiric anti-anaerobic antibiotics are associated with adverse clinical outcomes in emergency department patients. *Eur Respir J*. 2023;61(5):2300413. doi:10.1183/13993003.00413-2023
76. Jones BE, Ying J, Stevens V, et al. Empirical anti-MRSA vs standard antibiotic therapy and risk of 30-day mortality in patients hospitalized for pneumonia. *JAMA Intern Med*. 2020;180(4):552-560. doi:10.1001/jamainternmed.2019.7495
77. Aliberti S, Reyes LF, Faverio P, et al; GLIMP Investigators. Global Initiative for Meticillin-Resistant *Staphylococcus aureus* Pneumonia (GLIMP): an international, observational cohort study. *Lancet Infect Dis*. 2016;16(12):1364-1376. doi:10.1016/S1473-3099(16)30267-5
78. van Werkhoven CH, van de Garde EMW, Oosterheert JJ, Postma DF, Bonten MJM. Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy. *Respir Med*. 2017;129:145-151. doi:10.1016/j.rmed.2017.06.012
79. Pakhale S, Mulpuru S, Verheij TJ, Kochen MM, Rohde GG, Bjerre LM. Antibiotics for community-acquired pneumonia in adult outpatients. *Cochrane Database Syst Rev*. 2014;2014(10):CD002109. doi:10.1002/14651858.CD002109.pub4
80. Eraikhuemen N, Julien D, Kelly A, Lindsay T, Lazaridis D. Treatment of community-acquired pneumonia: a focus on lefamulin. *Infect Dis Ther*. 2021;10(1):149-163. doi:10.1007/s40121-020-00378-3
81. Li J, Peng Y, Li X. Meta-analysis of the effects of combination therapies of β -lactams and fluoroquinolones or macrolides in the treatment of community-acquired pneumonia. *Am J Transl Res*. 2021;13(4):2439-2446.
82. Xu LY, Wang CC, Peng XX, et al. Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis. *J Glob Antimicrob Resist*. 2022;30:1-9. doi:10.1016/j.jgar.2022.05.009
83. Hamao N, Ito I, Konishi S, et al. Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial. *BMC Pulm Med*. 2020;20(1):160. doi:10.1186/s12890-020-01198-4
84. Raz-Pasteur A, Shasha D, Paul M. Fluoroquinolones or macrolides alone versus combined with β -lactams for adults with community-acquired pneumonia: a systematic review and meta-analysis. *Int J Antimicrob Agents*. 2015;46(3):242-248. doi:10.1016/j.ijantimicag.2015.04.010
85. Bai F, Li X. Comparing several treatments with antibiotics for community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. *Iran J Public Health*. 2021;50(6):1108-1119. doi:10.18502/ijph.v50i6.6410
86. Kato H, Hagihara M, Asai N, et al. Comparison between ceftriaxone and sulbactam-ampicillin as initial treatment of community-acquired pneumonia: a systematic review and meta-analysis. *Antibiotics (Basel)*. 2022;11(10):1291. doi:10.3390/antibiotics11101291
87. Zhang YQ, Zou SL, Zhao H, Zhang MM, Han CL. Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: a meta-analysis. *Am J Emerg Med*. 2018;36(10):1759-1765. doi:10.1016/j.ajem.2018.01.079
88. Izadi M, Dadsetan B, Najafi Z, et al. Levofloxacin versus ceftriaxone and azithromycin combination in the treatment of community-acquired pneumonia in hospitalized patients. *Recent Pat Antiinfect Drug Discov*. 2018;13(3):228-239. doi:10.2174/1574891X13666181024154526
89. Vardakas KZ, Trigkidis KK, Falagas ME. Fluoroquinolones or macrolides in combination with β -lactams in adult patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2017;23(4):234-241. doi:10.1016/j.cmi.2016.12.002
90. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: a review. *JAMA*. 2019;321(2):188-199. doi:10.1001/jama.2018.19283
91. Chanderraj R, Admon AJ, He Y, et al. Mortality of patients with sepsis administered piperacillin-tazobactam or cefepime using instrumental variable analysis. *JAMA Intern Med*. 2024;184(7):769-777.
92. Dinh A, Ropers J, Admon AJ, et al; Pneumonia Short Treatment (PTC) Study Group. Discontinuing β -lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. *Lancet*. 2021;397(10280):1195-1203. doi:10.1016/S0140-6736(21)00313-5
93. Uranga A, España PP, Bilbao A, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. *JAMA Intern Med*. 2016;176(9):1257-1265. doi:10.1001/jamainternmed.2016.3633
94. Drehobl MA, De Salvo MC, Lewis DE, Breen JD. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. *Chest*. 2005;128(4):2230-2237. doi:10.1378/chest.128.4.2230
95. D'Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. *Antimicrob Agents Chemother*. 2005;49(10):4035-4041. doi:10.1128/AAC.49.10.4035-4041.2005
96. Furukawa Y, Luo Y, Funada S, et al. Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis. *BMJ Open*. 2023;13(3):e061023. doi:10.1136/bmjopen-2022-061023
97. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community-acquired pneumonia: randomised, double blind study. *BMJ*. 2006;332(7554):1355. doi:10.1136/bmj.332.7554.1355
98. Møller Gundersen K, Nygaard Jensen J, Bjerrum L, Hansen MP. Short-course vs long-course antibiotic treatment for community-acquired pneumonia: a literature review. *Basic Clin Pharmacol Toxicol*. 2019;124(5):550-559. doi:10.1111/bcpt.13205
99. Tansarli GS, Mylonakis E. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults. *Antimicrob Agents Chemother*. 2018;62(9):e00635-18. doi:10.1128/AAC.00635-18
100. Uranga A, Artaraz A, Bilbao A, et al. Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community-acquired pneumonia. *BMC Pulm Med*. 2020;20(1):261. doi:10.1186/s12890-020-01293-6

- 101.** Vaughn VM, Flanders SA, Snyder A, et al. Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: a multihospital cohort study. *Ann Intern Med.* 2019;171(3):153-163. doi:10.7326/M18-3640
- 102.** Tralhão A, Póvoa P. Cardiovascular events after community-acquired pneumonia: a global perspective with systematic review and meta-analysis of observational studies. *J Clin Med.* 2020;9(2):414. doi:10.3390/jcm9020414
- 103.** Ciarkowski CE, Timbrook TT, Kukhareva PV, et al. A pathway for community-acquired pneumonia with rapid conversion to oral therapy improves health care value. *Open Forum Infect Dis.* 2020;7(11):ofaa497. doi:10.1093/ofid/ofaa497
- 104.** Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. *JAMA.* 2016;315(6):593-602. doi:10.1001/jama.2016.0115
- 105.** Teshome BF, Park T, Arackal J, Hampton N, Kollef MH, Micek ST. Preventing new gram-negative resistance through beta-lactam de-escalation in hospitalized patients with sepsis: a retrospective cohort study. *Clin Infect Dis.* Published online June 6, 2024. doi:10.1093/cid/ciae253
- 106.** Dequin PF, Meziani F, Quenot JP, et al; CRICS-TriGGERSep Network. Hydrocortisone in severe community-acquired pneumonia. *N Engl J Med.* 2023;388(21):1931-1941. doi:10.1056/NEJMoa2215145
- 107.** Wittermans E, Vestjens SMT, Spoorenberg SMC, et al; Santeon-CAP Study Group; Members of the Santeon-CAP Study Group. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalized with community-acquired pneumonia: a randomised clinical trial. *Eur Respir J.* 2021;58(2):2002535. doi:10.1183/13993003.02535-2020
- 108.** Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2011;377(9782):2023-2030. doi:10.1016/S0140-6736(11)60607-7
- 109.** Saleem N, Kulkarni A, Snow TAC, Ambler G, Singer M, Arulkumaran N. Effect of corticosteroids on mortality and clinical cure in community-acquired pneumonia: a systematic review, meta-analysis, and meta-regression of randomized control trials. *Chest.* 2023;163(3):484-497. doi:10.1016/j.chest.2022.08.2229
- 110.** Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. *Chest.* 2016;149(1):209-219. doi:10.1378/chest.15-1733
- 111.** Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. *Ann Intern Med.* 2015;163(7):519-528. doi:10.7326/M15-0715
- 112.** Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. *Lancet.* 2015;385(9977):1511-1518. doi:10.1016/S0140-6736(14)62447-8
- 113.** Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. *Am J Respir Crit Care Med.* 2010;181(9):975-982. doi:10.1164/rccm.200905-0808OC
- 114.** Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. *JAMA.* 2015;313(7):677-686. doi:10.1001/jama.2015.88
- 115.** Wu JY, Tsai YW, Hsu WH, et al. Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. *Crit Care.* 2023;27(1):274. doi:10.1186/s13054-023-04561-z
- 116.** Meduri GU, Shih MC, Bridges L, et al; ESCAPE Study Group. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. *Intensive Care Med.* 2022;48(8):1009-1023. doi:10.1007/s00134-022-06684-3
- 117.** Wu WF, Fang Q, He GJ. Efficacy of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis. *Am J Emerg Med.* 2018;36(2):179-184. doi:10.1016/j.ajem.2017.07.050
- 118.** Bi J, Yang J, Wang Y, et al. Efficacy and safety of adjunctive corticosteroids therapy for severe community-acquired pneumonia in adults: an updated systematic review and meta-analysis. *PLoS One.* 2016;11(11):e0165942. doi:10.1371/journal.pone.0165942
- 119.** Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. *Egypt J Chest Dis Tuberc.* 2013;62(3):439-445. doi:10.1016/j.ejcdt.2013.03.009
- 120.** Sabry NA, El-Din Omar E. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. *Pharm Pharmacol.* 2011;2(2):73-81. doi:10.4236/pp.2011.22009
- 121.** Jiang S, Liu T, Hu Y, et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: a meta-analysis. *Medicine (Baltimore).* 2019;98(26):e16239. doi:10.1097/MD.00000000000016239
- 122.** Tanzella G, Motos A, Battaglini D, Meli A, Torres A. Optimal approaches to preventing severe community-acquired pneumonia. *Expert Rev Respir Med.* 2019;13(10):1005-1018. doi:10.1080/17476348.2019.1656531
- 123.** Ehrenzeller S, Klompas M. Association between daily toothbrushing and hospital-acquired pneumonia: a systematic review and meta-analysis. *JAMA Intern Med.* 2024;184(2):131-142. doi:10.1001/jamainternmed.2023.6638
- 124.** Liu DS, Han XD, Liu XD. Current status of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. *Chin Med J (Engl).* 2018;131(9):1086-1091. doi:10.4103/0366-6999.230727
- 125.** Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. *JAMA Intern Med.* 2017;177(9):1308-1315. doi:10.1001/jamainternmed.2017.1938
- 126.** Mo Y, Oonsivilai M, Lim C, Niehus R, Cooper BS. Implications of reducing antibiotic treatment duration for antimicrobial resistance in hospital settings: a modelling study and meta-analysis. *PLoS Med.* 2023;20(6):e1004013. doi:10.1371/journal.pmed.1004013
- 127.** Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current understanding of the human microbiome. *Nat Med.* 2018;24(4):392-400. doi:10.1038/nm.4517
- 128.** Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clin Microbiol Infect.* 2020;26(12):1622-1629. doi:10.1016/j.cmi.2020.07.016
- 129.** Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. *BMJ.* 2006;333(7580):1193. doi:10.1136/bmj.38993.560984.BE
- 130.** Horby P, Lim WS, Emberson JR, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med.* 2021;384(8):693-704. doi:10.1056/NEJMoa2021436
- 131.** Sterne JAC, Murthy S, Diaz JV, et al; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. *JAMA.* 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023
- 132.** Pirracchio R, Venkatesh B, Legrand M. Low-dose corticosteroids for critically ill adults with severe pulmonary infections: a review. *JAMA.* 2024;332(4):318-328. doi:10.1001/jama.2024.6096
- 133.** Lloyd M, Karahalios A, Janus E, et al; Improving Evidence-Based Treatment Gaps and Outcomes in Community-Acquired Pneumonia (IMPROVE-GAP) Implementation Team at Western Health. Effectiveness of a bundled intervention including adjunctive corticosteroids on outcomes of hospitalized patients with community-acquired pneumonia: a stepped-wedge randomized clinical trial. *JAMA Intern Med.* 2019;179(8):1052-1060. doi:10.1001/jamainternmed.2019.1438
- 134.** Cheema HA, Musheer A, Ejaz A, et al. Efficacy and safety of corticosteroids for the treatment of community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. *J Crit Care.* 2024;80:154507. doi:10.1016/j.jcrc.2023.154507
- 135.** Boussat B, Cazzorla F, Le Marechal M, et al. Incidence of avoidable 30-day readmissions following hospitalization for community-acquired pneumonia in France. *JAMA Netw Open.* 2022;5(4):e226574. doi:10.1001/jamanetworkopen.2022.6574